<DOC>
	<DOCNO>NCT00199251</DOCNO>
	<brief_summary>· To evaluate efficacy rupatadine 10 20 mg treatment CIU symptoms four-week treatment period comparison placebo .</brief_summary>
	<brief_title>Efficacy Safety Rupatadine 10 20 Mg Chronic Idiopathic Urticaria</brief_title>
	<detailed_description>STUDY PHASE III OBJECTIVES · To evaluate efficacy safety rupatadine 10 mg 20 mg treatment CIU symptoms four-week treatment period comparison placebo . DESIGN · A multicentre , double blind , randomise , placebo control , parallel–group study 300 patient ( 100 patient treatment ) group . INDICATION · Chronic Idiopathic Urticaria ( CIU ) ASSESSMENT Primary efficacy measure treatment compare frequency severity symptom CIU measure patient term change mean pruritus score ( MPS ) 4-week treatment period.Secondary efficacy measure include change baseline 4 6-week treatment period mean number wheal ( MNW ) score ; mean total symptom score ( MTSS ) , calculate sum MPS ( Mean pruritus symptom ) MNW ( Mean number wheal ) score , severity symptom CIU measure patient term change mean pruritus score ( MPS ) 6-week treatment period , Visual Analogic Scale ( VAS ) Quality life ( QoL ) assess “ Dermatology Life Quality Index ” ( DLQI ) .Safety : ECGs baseline final visit ; clinical laboratory control , physical examination , incidence adverse event ( AE ) . STUDY POPULATION 300 patient 12-65 year age , CIU</detailed_description>
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Cyproheptadine</mesh_term>
	<criteria>1 . Man woman age 12 65 2 . Active CIU ( score ³2 label moderate pruritus ) least 3 day ( necessarily consecutive day ) week inclusion total score active CIU ³6 label moderate pruritus 3 day 3 . Documented history active CIU ( urticaria wheal ) without associate angioedema least three day per week last 6 week prior Screening Visit . 4 . 12 lead ECG obtain screen within acceptable limit , moreover absence drug effect disease , QTc interval value ( msec ) Bazzet ’ correction must normal ( prolong ) . The value consider normal &lt; 430 msec male &lt; 450 msec female . 5 . Patient sign informed consent form . In case patient underage ( 12 18 , 21 Argentina ) write informed consent one his/her parent legal guardian require . 6 . Women childbearing potential negative pregnancy test time inclusion . In addition , must use effective contraceptive method ( i.e . oral , IUD , condom , etc ) . The commitment patient use measure participate clinical trial consider sufficient . 1 . CIU associate underlying disease ( Hodgkin ’ disease/vasculitis/lupus erythematous/hepatitis ) 2 . Patient systemic topical medication CIU and/or inferior washout period state follow : H1receptor antagonist : fexofenadine ( 5 day prior Day 0 ) , loratadine , desloratadine , cetirizine , hydroxyzine , diphenhydramine , cyproheptadine , etc . ( 3 day prior Day 0 ) H2receptor antagonist : cimetidine , ranitidine , famotidine , etc ( 2 day prior Day 0 ) H1 H2receptor antagonist : doxepin ( 7 day prior Day 0 ) Leukotriene antagonist : zafirlukast , montelukast , etc ( 4 day prior Day 0 ) Corticosteroids : prednisone , methylprednisolone , etc ( 28 day prior Day 0 ) Tricyclic antidepressant : imipramin , amitriptilin , etc ( 30 day prior Day 0 ) The informed consent form must sign prior washout period set . 3 . Patients analytical value twice high upper limit normality follow parameter : ALP , ALT , AST , GGT creatinine , 1,5 time high upper limit normality CK . Any laboratory relevant find assessed investigator patient inclusion . 4 . Cholinergic urticaria . 5 . Patient take medication know interact CYP3A4 isozyme cytochrome P450 amiodarone , carbamazepine , cyclosporin , terfenadine , glucocorticoid , phenytoin , rifampicin , macrolides ( e.g . erythromycin , clarytomicine , etc ) antifungal ( e.g . ketoconazole , miconazole , fluconazole , etc ) well grapefruit juice . 6 . Urticaria due know etiology ( e.g . medication , insect bite , food , cold/heat , sun , etc ) 7 . Patient review medical history , consider investigator unresponsive antihistaminic treatment 8 . Pregnant lactate female 9 . Patients currently participate participate another clinical trial within last three month 10 . Patients recent history ( within previous 12 month ) drug addiction alcohol abuse 11 . Patient take drug strongly associate torsade de pointes disopyramide , procainamide , quinidine , amiodarone , sotalol , thioridazine , beperidil prenylamine . 12 . Patient treatment could lead symptomatic relief urticaria symptom , example : cream , lotion , ointment , homeopathy , etc… without recognize active ingredient . ( ../ . )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>URTICARIA , WHEALS , FLARE , ANTIHISTAMINE , ANTIHISTAMINE</keyword>
</DOC>